IN2014DN09940A - - Google Patents

Info

Publication number
IN2014DN09940A
IN2014DN09940A IN9940DEN2014A IN2014DN09940A IN 2014DN09940 A IN2014DN09940 A IN 2014DN09940A IN 9940DEN2014 A IN9940DEN2014 A IN 9940DEN2014A IN 2014DN09940 A IN2014DN09940 A IN 2014DN09940A
Authority
IN
India
Prior art keywords
melatonin
field
memantine
capsules
pharmaceutical
Prior art date
Application number
Inventor
Margarita Alekseevna Morozova
Allan Gerovich Beniashvili
Maxim Eduardovich Zapolsky
Original Assignee
Valenta Intellekt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valenta Intellekt Ltd filed Critical Valenta Intellekt Ltd
Publication of IN2014DN09940A publication Critical patent/IN2014DN09940A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to the field of medicine and the pharmaceutical- chemical industry, and specifically to the field of neurology , and concerns new compositions containing memantine and melatonin. It has been established that a strengthening of the effect of memantine takes place when it is combined with melatonin. The invention may be realized through the preparation of a finished pharmaceutical product such as capsules, preferably hard gelatin capsules.
IN9940DEN2014 2012-05-24 2012-10-31 IN2014DN09940A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2012121410/15A RU2488388C1 (en) 2012-05-24 2012-05-24 Pharmaceutical composition for preventing and treating mental, behaviour and cognitive disorders
PCT/RU2012/000888 WO2013176567A1 (en) 2012-05-24 2012-10-31 Pharmaceutical composition for the prophylaxis and treatment of psychological, behavioral and cognitive disorders

Publications (1)

Publication Number Publication Date
IN2014DN09940A true IN2014DN09940A (en) 2015-08-14

Family

ID=49155569

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9940DEN2014 IN2014DN09940A (en) 2012-05-24 2012-10-31

Country Status (14)

Country Link
US (1) US20150157604A1 (en)
EP (1) EP2857011A4 (en)
JP (1) JP5864819B2 (en)
KR (1) KR101581611B1 (en)
CN (1) CN104334166A (en)
AU (1) AU2012380583B2 (en)
CA (1) CA2873891C (en)
EA (1) EA201400973A1 (en)
HK (1) HK1205467A1 (en)
IL (1) IL235852A0 (en)
IN (1) IN2014DN09940A (en)
RU (1) RU2488388C1 (en)
UA (1) UA112352C2 (en)
WO (1) WO2013176567A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2536270C1 (en) * 2013-10-21 2014-12-20 Общество с ограниченной ответственностью ООО "ВАЛЕНТА ИНТЕЛЛЕКТ" Combination for correction of neurologic and psychoemotional status in case of organic cns disorders
US10265497B2 (en) 2015-11-24 2019-04-23 Massachusetts Institute Of Technology Systems and methods for treating dementia
RU2654713C1 (en) * 2016-06-29 2018-05-22 Общество С Ограниченной Ответственностью "Валента-Интеллект" Pharmaceutical composition containing the combination of memantine and melatonin
RU2623865C1 (en) * 2016-06-29 2017-06-29 Общество С Ограниченной Ответственностью "Валента-Интеллект" Pharmaceutical composition containing memantine and melatonin combination
CA3029382C (en) * 2016-06-29 2021-10-12 Ltd "Valenta-Intellekt" Pharmaceutical composition containing combination of memantine and melatonin
ES3009413T3 (en) 2016-10-31 2025-03-26 Neurim Pharma 1991 Melatonin mini-tablets and method of manufacturing the same
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
EP4366469A3 (en) 2016-11-17 2024-05-22 Cognito Therapeutics, Inc. Methods and systems for neural stimulation via visual stimulation
US10960225B2 (en) * 2017-10-10 2021-03-30 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function
AU2018347870B2 (en) 2017-10-10 2022-12-08 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7305644A (en) 1972-04-20 1973-10-23
DE2856393C2 (en) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Medicines used to treat Parkinson's disease
EP0392059B1 (en) 1989-04-14 1993-09-15 Merz & Co. GmbH & Co. Use of adamantane derivatives in the prevention and treatment of cerebral ischemia
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US6469044B1 (en) 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
KR100630506B1 (en) * 1997-06-30 2006-09-29 메르츠 파마 게엠베하 운트 코. 카가아 1-amino-alkylcyclohexane compound as NMDA receptor antagonist, pharmaceutical composition containing the same and method of treating with it
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20050129783A1 (en) * 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
DK1562585T3 (en) 2002-10-30 2011-03-14 Asat Ag Applied Science & Tech Daily melatonin dosing units
RU2268737C2 (en) 2004-02-16 2006-01-27 Государственное учреждение институт клинической иммунологии СО РАМН Method for treatment of atopic dermatitis
CN1968684A (en) * 2004-06-17 2007-05-23 森林实验室公司 Modified release formulation of memantine
WO2007049098A2 (en) * 2004-06-18 2007-05-03 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
JP2008514620A (en) * 2004-09-23 2008-05-08 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン Memantine for the treatment of pediatric behavioral disorders
MY148806A (en) * 2005-04-04 2013-05-31 Takeda Pharmaceutical Prophylactic or therapeutic agent for nocturnal conduct disorder associated with dementia
CN1709230A (en) * 2005-07-05 2005-12-21 北京阜康仁生物制药科技有限公司 Memantine hydrochloride dispersable table and its preparing method
RU2294741C1 (en) 2005-08-08 2007-03-10 Рина Михайловна Заславская Method for treating patients with ischemic cardiac disease, stable stenocardia in combination with arterial hypertension
US20090209638A1 (en) * 2006-05-22 2009-08-20 Gunther Birznieks Treatment for depressive disorders
AU2007253684A1 (en) * 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Treatment for depressive disorders
JP2009542647A (en) * 2006-07-05 2009-12-03 テバ ファーマシューティカル インダストリーズ リミティド Memantine pharmaceutical composition
US20080008743A1 (en) * 2006-07-06 2008-01-10 Forest Laboratories Holdings Limited Orally Dissolving Formulations of Memantine
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
RU2326660C1 (en) 2007-03-14 2008-06-20 Закрытое акционерное общество "Биологические исследования и системы" Oral pharmaceutical composition memantin (options) and method of preparation (options)
CA2683436C (en) 2007-04-11 2016-07-26 John A. Mccarty Melatonin tablet and methods of preparation and use
BRPI0811052A2 (en) 2007-04-12 2015-01-27 Univ Minnesota ISCHEMIA / REPERFUSION PROTECTION COMPOSITIONS AND METHODS OF USE.
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
AU2010211220B2 (en) * 2009-02-06 2013-08-01 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
RU2394571C1 (en) 2009-05-14 2010-07-20 Государственное бюджетное учреждение здравоохранения города Москвы "Городская клиническая больница № 24" Департамента здравоохранения города Москвы Method of treating inflammatory intestinal diseases
RU2418586C2 (en) 2009-06-11 2011-05-20 Государственное образовательное учреждение высшего профессионального образования "Новосибирский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО НГМУ Росздрава) Method of correcting failures in reproductive organs caused by high temperature
RU2428183C1 (en) 2010-07-01 2011-09-10 Рина Михайловна Заславская Adaptogen for meteosensitive patients with stenocardia and arterial hypertension and application of melatonin as adaptogen

Also Published As

Publication number Publication date
CN104334166A (en) 2015-02-04
HK1205467A1 (en) 2015-12-18
EA201400973A1 (en) 2015-02-27
EP2857011A4 (en) 2015-12-02
WO2013176567A1 (en) 2013-11-28
KR20150005999A (en) 2015-01-15
UA112352C2 (en) 2016-08-25
JP2015517569A (en) 2015-06-22
AU2012380583B2 (en) 2015-01-22
EP2857011A1 (en) 2015-04-08
CA2873891C (en) 2016-02-16
RU2488388C1 (en) 2013-07-27
IL235852A0 (en) 2015-01-29
KR101581611B1 (en) 2015-12-31
US20150157604A1 (en) 2015-06-11
CA2873891A1 (en) 2013-11-28
JP5864819B2 (en) 2016-02-17
AU2012380583A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
IN2014DN09940A (en)
TN2015000278A1 (en) Autotaxin inhibitors
PH12016500094A1 (en) Autotaxin inhibitors
PT3674298T (en) Substituted indazoles, process for their preparation, pharmaceutical formulations containing them, and their use for the preparation of medicaments
GB201106743D0 (en) Novel compounds
IL233602A (en) Benzamide derivatives, their preparation and pharmaceutical compositions containing them
UA116889C2 (en) COMPOSITION COMPRISING A MIXTURE OF CD95-Fc ISOFORMS
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
IN2013MU03918A (en)
PH12017500348A1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MX2020009444A (en) Low dose oral pharmaceutical composition of isotretinoin.
IN2014DN10449A (en)
MX2017015137A (en) Once daily oral pharmaceutical composition of isotretinoin.
HUP1300647A2 (en) Complexes of cyclosporine a and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
IL237688A0 (en) Syringe containing a composition, especially a pharmaceutical composition, comprising immunoglobins, methods for the production thereof and use of same
MX2014004210A (en) 2-oxo-piperidinyl derivatives.
MD4615B1 (en) Isolated solid form of anamorelin monohydrochloride, pharmaceutical composition and method of making a pharmaceutical dosage form comprising it
WO2015044434A3 (en) Fluor-9-methyl-β-carbolines
AP2012006308A0 (en) New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them.
IN2014MN01492A (en)
WO2014122671A3 (en) Solid oral compositions of saxagliptin
IN2013MU03317A (en)
IN2014DN07897A (en)
IN2015MN00091A (en)
IN2015DN02660A (en)